NPI | Name | Type | Address |
---|---|---|---|
DR. PHARM.D Leila Rostamnjad |
Individual |
50 Fruit St Boston, MA |
|
PHARMD Cynthia Hinds |
Individual |
1708 Yakima Ave Suite 203 Tacoma, WA |
|
Ferowsi Pecoraro |
Individual |
1708 Yakima Ave Suite 203 Tacoma, WA |
|
PHARMD Alissa Karr |
Individual |
800 Rose St # Wh330 Lexington, KY |
|
PHARMD Emily Eastman |
Individual |
800 Rose St Lexington, KY |
|
PHARMD Joon Hwang |
Individual |
3701 Broadway Oakland, CA |
|
PHARMD Shawn Hagland |
Individual |
1708 Yakima Ave Suite 203 Tacoma, WA |
|
PHARMD Inna Vasilyev |
Individual |
1708 Yakima Ave Suite 203 Tacoma, WA |
|
PHARMD Christine Ibrahim |
Individual |
1708 Yakima Ave Suite 203 Tacoma, WA |
|
Laura Erlewine |
Individual |
505 Ne 87th Ave Suite 320 Vancouver, WA |
|
PHARMD Sharleen Huon |
Individual |
1708 Yakima Ave Suite 203 Tacoma, WA |
|
DR. PHARMD, BCPS, BCOP Jennifer Lynn Reddy |
Individual |
2200 River Plaza Drive Sacramento, CA |
|
PHARMD Madeline Waldron |
Individual |
9500 Euclid Ave Jjn1-200 Cleveland, OH |
|
DR. PHARMD Bernadette Catherine Loughlin |
Individual |
1275 York Ave Room C-1087 New York, NY |
|
Donna Michelle Smith |
Individual |
162 Eastfield Ct Alpharetta, GA |
|
MS. RPH Gayla Dawn Curl |
Individual |
211 Nw 131st St Vancouver, WA |
|
PHARMD Eno Inyang |
Individual |
1717 S J St Ms 01-79 Tacoma, WA |
|
DR. PHARMD Raymond B. Elliott |
Individual |
547 Tanbridge Rd Wilmington, NC |
|
DR. PHARMD Denise Lynn Meyer |
Individual |
4444 Tamarind Way Naples, FL |
|
DR. PHARMD Yi Gao-roberts |
Individual |
20 Meadow Ln Boxborough, MA |
Every health care provider, whether it’s a hospital, pharmacy, or individual specialist, must obtain their own NPI number. This identification number is unique and is assigned upon application. In tod...
Taxonomy Code | 1835X0200X |
Specialization | Oncology |
Display Name | Oncology Pharmacist |
Taxonomy Group | Pharmacy Service Providers |
Taxonomy Classification | Pharmacist |
Definition | A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases. |
Effective Date | September 30, 2009 |